Abstract
This study presents composite nanoparticles combining cobalt ferrites-oleic acid (CF-OA) and mesoporous silica (MCM-41) for drug delivery. Temperature-dependent analyses at 25 and 42 °C reveal distinct alterations in particle size and distribution, emphasizing the role of oleate complexes in stabilizing the nanocomposites. Power of Laws calculations (n = 0.58, m = 0.44) assessed diffusion and matrix erosion effects, highlighting the pH-responsive behavior. Results showed CF-OA@MCM-41with nanometric scale and predominantly spherical morphology influenced by temperature variations. Nitrogen BET analysis revealed a surface area of 542.1 m2g−1 and a pore volume of 1.1 cm3g−1. Drug release studies demonstrated controlled doxorubicin (DOX) release from CF-OA@MCM-41. In vivo studies showed significant tumor growth suppression (liver cancer): average tumor volume in D-C@M group was 167.8 mm3 after 21 days, compared to 1953.8 mm3, 1203.6 mm3, and 269 mm3 for PBS, CF-OA@MCM-41, and DOX alone respectively. In vitro, a 3 µg mL−1 concentration showed no significant 293 T cell viability change and increased HEP G2 cell viability. Significant HEP G2 cell viability inhibition occurred at 1 and 2 µg mL−1 CF-OA@MCM-41 carrying DOX, with p-values < 0.01 and < 0.001. CF-OA@MCM-41 nanoparticles exhibit promising potential for targeted cancer therapy due to their pH sensitivity and controlled drug release capabilities.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
